Posts

Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer

Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
arcticnovartis

  • Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between anatomical stages1

  • Real-world 5-year distant recurrence data in high-risk patients with HR+/HER2- early breast cancer (EBC), regardless of nodal status, highlights importance of adding a CDK4/6 inhibitor to endocrine therapy for all eligible patients2
/by
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
arcticnovartis

  • Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key secondary endpoints1
     
  • Scemblix showed a clinically relevant 15.1% higher MMR rate vs. second generation (2G) TKIs (72.0% vs. 56.9%)1
/by
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
arcticnovartis

  • In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were switched from anti-C5 therapies (Hb ≥10g/dL following treatment with eculizumab or ravulizumab)1,2
/by
Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington’s disease

Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington’s disease
imberje1

/by
Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence

Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
arcticnovartis

  • Approval is based on Phase III NATALEE data showing Kisqali® (ribociclib) plus adjuvant endocrine therapy (ET) demonstrated clinically meaningful invasive disease-free survival (iDFS) benefit in patients with stage II or III HR+/HER2- early breast cancer (EBC), consistent across all subgroups1,2
/by
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS

Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
arcticnovartis

  • Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data
  • Late-breaking Kisqali®* 4-year analysis on distant disease-free survival in key subgroups with HR+/HER2- early breast cancer from Phase III NATALEE trial also to be presented
/by
Biologist to Head-hunter

Biologist to Head-hunter
mihai_novartis

/by
Addressing unmet needs for inherited neuromuscular diseases

Addressing unmet needs for inherited neuromuscular diseases
angilma1

/by
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis ranks first in 2024 Access to Medicine Index

Novartis ranks first in 2024 Access to Medicine Index
arcticnovartis

  • The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics
  • Novartis malaria access plans, widespread registration of products in LMICs, and inclusive business model to improve access to products in multiple countries were all highlighted as Best Practice across the industry
  • Novartis has risen three places to secure the top spot on the 2024 Access to Medicine Index
/by